Containment technology for small-scale solid dosage at Penn Pharma

After conducting extensive market research, Penn Pharma identified an increased need in the solid dose oncology market for the outsourced development and production of highly toxic drugs. Its production site had been manufacturing potent solid dosage products for more than 20 years but needed additional capacity. Penn Pharma elected to work with GEA because of its proven track record in containment technology and expertise in creating fully integrated production lines.